1. Home
  2. FRST vs IMMP Comparison

FRST vs IMMP Comparison

Compare FRST & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primis Financial Corp.

FRST

Primis Financial Corp.

HOLD

Current Price

$13.40

Market Cap

261.7M

Sector

Finance

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.46

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRST
IMMP
Founded
2004
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.7M
264.9M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
FRST
IMMP
Price
$13.40
$2.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
86.1K
1.7M
Earning Date
01-27-2026
02-22-2026
Dividend Yield
2.99%
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$138,816,000.00
$3,306,742.00
Revenue This Year
$13.75
N/A
Revenue Next Year
$35.05
N/A
P/E Ratio
$39.35
N/A
Revenue Growth
33.08
31.28
52 Week Low
$7.59
$1.32
52 Week High
$13.46
$3.53

Technical Indicators

Market Signals
Indicator
FRST
IMMP
Relative Strength Index (RSI) 80.14 66.08
Support Level $11.01 $1.67
Resistance Level $12.47 $2.68
Average True Range (ATR) 0.34 0.26
MACD 0.21 0.08
Stochastic Oscillator 95.44 41.94

Price Performance

Historical Comparison
FRST
IMMP

About FRST Primis Financial Corp.

Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: